Skip to main content
Addgene

pLKO.1puro-shKIBRA-B
(Plasmid #40889)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 40889 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pLKO.1 puro
  • Backbone manufacturer
    Addgene 8453
  • Backbone size w/o insert (bp) 7032
  • Total vector size (bp) 7079
  • Vector type
    Mammalian Expression, Lentiviral, RNAi
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    shKIBRA-B
  • Alt name
    WWC1
  • gRNA/shRNA sequence
    TGGTACAACCTTCTCAGCT
  • Species
    H. sapiens (human)
  • Entrez Gene
    WWC1 (a.k.a. HBEBP3, HBEBP36, KIBRA, MEMRYQTL, PPP1R168)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site AgeI (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer pLKO.1 seq
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLKO.1puro-shKIBRA-B was a gift from Paul Reynolds (Addgene plasmid # 40889 ; http://n2t.net/addgene:40889 ; RRID:Addgene_40889)
  • For your References section:

    KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals. Moleirinho S, Chang N, Sims AH, Tilston-Lunel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy C, Faratian D, Gunn-Moore FJ, Reynolds PA. Oncogene. 2012 May 21. doi: 10.1038/onc.2012.196. 10.1038/onc.2012.196 PubMed 22614006